Puma Biotechnology | Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agios Pharmaceuticals USD 41.27M 4.6M 2025-09
Alnylam Pharmaceuticals USD 262.59M 60.72M 2025-09
Amgen USD 1.94B 237M 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 223.42M 8.86M 2025-09
Daiichi Sankyo JPY 228.23B 39.15B 2025-12
Esperion Therapeutics USD 39.98M 4.21M 2024-09
Exelixis USD 103.13M 9.8M 2025-09
Gilead Sciences USD 1.35B 6M 2025-09
Glaxosmithkline GBP 2.91B 817.89M 2025-09
Incyte USD 390.41M 61.33M 2025-12
MacroGenics USD 9.9M 600K 2025-09
Moderna USD 268M 38M 2025-09
Novartis USD 3.31B 134M 2025-09
Pfizer USD 4.08B 894M 2025-12
PTC Therapeutics USD 84.05M 1.22M 2025-09
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 77.11M 7.22M 2025-09
Takeda JPY 282.78B 29.23B 2025-12
TG Therapeutics USD 63.37M 51.33M 2025-09
Ultragenyx Pharmaceutical USD 86.62M 26K 2025-09
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12
Vertex Pharmaceuticals USD 445.1M 20.5M 2025-09


Puma Biotechnology Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.